1. You are here:
  2. Homepage
  3. News & Insights Search

News & Insights Search

Displaying 10 of 1523 results
Active filters: United States
FDA_HQ3_260416_ALF.png
13 Oct 2026

Wide range of parties ask FDA to be flexible, protect patients when regulating psychedelic drugs

Stakeholders are urging the US Food and Drug Administration (FDA) to be flexible in how it regulates psychedelic drugs that may help treat conditions such as major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The agency should be careful not to create unnecessary barriers to patient access, promote proper training and credentialing, and allow flexibility in updating labeling as additional knowledge becomes available, according to individuals and groups that commented via a public docket.

Regulatory News
Week-FDA-RF-Dept-380x215.png
09 Oct 2026

This Week at FDA: HHS vaccine injury initiative, midterms could reshape congressional committees overseeing FDA, and more

Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical device regulation, and what we’re reading from around the web. This week, the Department of Health and Human Services (HHS) announced an agency-wide initiative to study and address vaccine injuries, and the congressional committees that oversee FDA could see high turnover after the midterm elections.

This Week at FDA
pills_drug_manufacturing_iStock-1465073112.jpg
09 Oct 2026

Study: Growing patent thickets may hinder generic competition

Over the last 15 years, there has been an uptick in the number of patents associated with small-molecule drugs approved by the US Food and Drug Administration (FDA), with a majority of the increase linked to the use of non-primary patents, according to the results of a recent special communication published in JAMA.

Regulatory News
See more